AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Enact Holdings Inc.
Video analysis: ACT
All videosNo video analysis for this stock yet. Request one from our team.
News: ACT
Implied Volatility Surging for Enact Holdings Stock Options
Investors need to pay close attention to ACT stock based on the movements in the options market lately.
ACT Capital Advisors Represents Advanced Marketing Group, LLC on Its Acquisition by StoneX Commodity Solutions, LLC
SEATTLE, Aug. 19, 2026 /PRNewswire/ -- ACT Capital Advisors, a premier investment bank serving founder-led and privately held companies, is pleased to announce the successful acquisition of its client, Advanced Marketing Group, LLC ("AMG"), by StoneX Commodity Solutions LLC, a subsidiary of StoneX Group Inc. ("StoneX": NASDAQ: SNEX). ACT Capital Advisors Managing Directors Stephen Spencer and Ron Huff, along with Associate Zack Hsieh, served as advisors to AMG on the transaction.
Aduro Selects Saipem for Engineering and Procurement Support for First-of-a-Kind HCT Facility at Chemelot
LONDON, Ontario, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc . (“Aduro” or the “Company”) (Nasdaq: ADUR) (TSX: ACT) (FSE: 9D5), a clean technology company using the power of chemistry to transform lower-value feedstocks, like waste plastics, heavy bitumen, and renewable oils, into resources for the 21st century, today announced the selection of Saipem S.p.A.
Dividend Champion, Contender, And Challenger Highlights: Week August 16
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
Enact Holdings, Inc. (ACT) Q2 2026 Earnings Call Transcript
Enact Holdings, Inc. (ACT) Q2 2026 Earnings Call Transcript
Enact Holdings, Inc. (ACT) Q2 Earnings and Revenues Top Estimates
Enact Holdings, Inc. (ACT) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Estimate of $1.2 per share. This compares to earnings of $1.15 per share a year ago.
Enact Reports Second Quarter 2026 Results; Announces $0.24 Quarterly Dividend
GAAP Net Income of $175 million , or $1.25 per diluted share Adjusted Operating Income of $177 million , or $1.26 per diluted share Return on Equity of 13.0% and Adjusted Operating Return on Equity of 13.2% Primary Insurance in-force of $274 billion , a 2% year-over-year increase PMIERs Sufficiency of 161% or approximately $1.9 billion Book Value Per Share of $39.06 and Book Value Per Share excluding AOCI of $39.66 Increased Full-Year Capital Return Guidance to be between $550 million and $600 million
Decoy Therapeutics Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMP³ACT™ Platform
Portfolio now spans seven patent families and 19 pending applications across seven jurisdictions, protecting antiviral peptide conjugates, the methods used to make them, their formulations, and the design platform behind them CAMBRIDGE, Mass., Aug. 3, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a biotechnology company developing Designable Multi-Antivirals (D-MAVs™), today announced continued expansion of its intellectual property portfolio, which now comprises seven patent families covering compositions of matter, methods of manufacture, formulations, and the company's IMP³ACT™ design platform.
Similar companies
-
Essent Group Ltd.
ESNT
·
New York Stock Exchange
Compare
-
Radian Group Inc.
RDN
·
New York Stock Exchange
Compare
-
MGIC Investment Corporation
MTG
·
New York Stock Exchange
Compare
-
Assured Guaranty Ltd.
AGO
·
New York Stock Exchange
Compare
-
NMI Holdings, Inc.
NMIH
·
NASDAQ
Compare
-
Lancashire Holdings Limited
LCSHF
·
Other OTC
Compare